Last reviewed · How we verify
XBD173
At a glance
| Generic name | XBD173 |
|---|---|
| Also known as | Emapunil, AC5216 |
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Endothelial Cell Activation and Total Pulmonary Resistance in PAH (NA)
- TSPO Occupancy in the Human Lung (NA)
- TSPO Modulation in AD (PHASE2)
- Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease (NA)
- Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target (NA)
- Reproducibility of the 11C-PBR28 PET Signal (NA)
- Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XBD173 CI brief — competitive landscape report
- XBD173 updates RSS · CI watch RSS
- Imperial College London portfolio CI